We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Ultragenyx (RARE - Free Report) . Shares have lost about 9.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Ultragenyx due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Ultragenyx Reports Wider-Than-Expected Loss in Q2
Ultragenyx reported adjusted loss per share of $1.89 in the second quarter of 2019 compared with a loss of $1.87 in the year-ago quarter. The loss was also wider than the Zacks Consensus Estimate of a loss of $1.73. The adjusted loss excludes unrealized gain from the fair value adjustment on the investment in Arcturus equity.
For the second quarter, Ultragenyx reported $24.1 million in total revenues, up from $12.8 million in the year-ago quarter. Revenues exceeded the Zacks Consensus Estimate of $22 million.
Ultragenyx recognized $20.2 million in total Crysvita revenues. This includes $17.3 million of collaboration revenues in the U.S. profit share territory and $1.9 million of royalty revenues in the European territory from the collaboration and license agreement with Japanese partner, Kyowa Hakko Kirin. Net product sales for Crysvita in other regions were $1 million. Revenues also include $0.1 million received from Bayer in relation to Ultragenyx’s research agreement with the former to develop adeno-associated virus gene therapies. Mepsevii product revenues were $3.2 million and UX007 revenues were $0.6 million.
Please note that though UX007 is not an approved product, the company recognizes sales from the candidate on a “named patient” basis. This is allowed in certain countries prior to the commercial approval of a product.
Crysvita is approved in the United States for the treatment of X-linked hypophosphatemia (XLH) in patients aged one year or older. The drug continues to deliver a strong performance in the United States. It was approved in Brazil for the treatment of XLH in patients aged a year or older.
Mepsevii, an enzyme replacement therapy, is the first and the only medicine approved for the treatment of children and adults with mucopolysaccharidosis VII (MPS VII) in the United States.
Pipeline Updates
The company submitted a new drug application (NDA) to the FDA for UX007 for the treatment of Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD). The company expects to hear back from the agency on submission acceptance and review designation within 60 days.
The company reported positive longer-term results from the first cohort of phase I/II study of DTX401 gene therapy in Glycogen Storage Disease Type Ia (GSDIa). Data from the second-dose cohort of the phase I/II study in GSDIa is expected in the third quarter of 2019.
The company reported data from the first two dose cohorts of DTX301 gene therapy in Ornithine Transcarbamylase (OTC) deficiency. The data demonstrated that the two responders maintained ureagenesis levels above normal for 78 and 52 weeks. DTX301 phase I/II data from the third dose cohort are expected in the third quarter of 2019.
The company expanded the research collaboration and the license agreement collaboration with Arcturus Therapeutics to develop additional nucleic acid therapies. The agreement with Arcturus Therapeutics now includes the discovery and development of mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets
How Have Estimates Been Moving Since Then?
Estimates revision followed an upward path over the past two months.
VGM Scores
At this time, Ultragenyx has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Ultragenyx has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Ultragenyx (RARE - Free Report) . Shares have lost about 9.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Ultragenyx due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Ultragenyx Reports Wider-Than-Expected Loss in Q2
Ultragenyx reported adjusted loss per share of $1.89 in the second quarter of 2019 compared with a loss of $1.87 in the year-ago quarter. The loss was also wider than the Zacks Consensus Estimate of a loss of $1.73. The adjusted loss excludes unrealized gain from the fair value adjustment on the investment in Arcturus equity.
For the second quarter, Ultragenyx reported $24.1 million in total revenues, up from $12.8 million in the year-ago quarter. Revenues exceeded the Zacks Consensus Estimate of $22 million.
Ultragenyx recognized $20.2 million in total Crysvita revenues. This includes $17.3 million of collaboration revenues in the U.S. profit share territory and $1.9 million of royalty revenues in the European territory from the collaboration and license agreement with Japanese partner, Kyowa Hakko Kirin. Net product sales for Crysvita in other regions were $1 million. Revenues also include $0.1 million received from Bayer in relation to Ultragenyx’s research agreement with the former to develop adeno-associated virus gene therapies. Mepsevii product revenues were $3.2 million and UX007 revenues were $0.6 million.
Please note that though UX007 is not an approved product, the company recognizes sales from the candidate on a “named patient” basis. This is allowed in certain countries prior to the commercial approval of a product.
Crysvita is approved in the United States for the treatment of X-linked hypophosphatemia (XLH) in patients aged one year or older. The drug continues to deliver a strong performance in the United States. It was approved in Brazil for the treatment of XLH in patients aged a year or older.
Mepsevii, an enzyme replacement therapy, is the first and the only medicine approved for the treatment of children and adults with mucopolysaccharidosis VII (MPS VII) in the United States.
Pipeline Updates
The company submitted a new drug application (NDA) to the FDA for UX007 for the treatment of Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD). The company expects to hear back from the agency on submission acceptance and review designation within 60 days.
The company reported positive longer-term results from the first cohort of phase I/II study of DTX401 gene therapy in Glycogen Storage Disease Type Ia (GSDIa). Data from the second-dose cohort of the phase I/II study in GSDIa is expected in the third quarter of 2019.
The company reported data from the first two dose cohorts of DTX301 gene therapy in Ornithine Transcarbamylase (OTC) deficiency. The data demonstrated that the two responders maintained ureagenesis levels above normal for 78 and 52 weeks. DTX301 phase I/II data from the third dose cohort are expected in the third quarter of 2019.
The company expanded the research collaboration and the license agreement collaboration with Arcturus Therapeutics to develop additional nucleic acid therapies. The agreement with Arcturus Therapeutics now includes the discovery and development of mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets
How Have Estimates Been Moving Since Then?
Estimates revision followed an upward path over the past two months.
VGM Scores
At this time, Ultragenyx has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Ultragenyx has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.